ArticleFrontiers in medical technology2026
Iron-oxide nanoparticle-integrated soft contact lenses: optical optimization, catalytic functionality, and biocompatibility.
Article in Frontiers in medical technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Millions of people suffer from corneal infections and inflammatory conditions, and a contact lens that not only corrects vision but also continuously protects against microbes and inflammation could transform ocular therapeutics. Compared with plasmonic metal nanoparticles, such as silver or gold, iron oxide nanoparticles are well known for their biocompatibility, low toxicity, and low cost. To our knowledge, this work is the first to demonstrate the integration of iron oxide nanoparticles into commercial contact lenses. Nanoparticles were characterized using X-ray diffraction, X-ray photoelectron spectroscopy, scanning electron microscopy and transmission electron microscopy. Optical properties were assessed using UV-Vis spectroscopy and COMSOL simulations. Catalytic activity was evaluated by methylene blue degradation in the presence of H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.